Compare · BXRX vs VMD
BXRX vs VMD
Side-by-side comparison of Baudax Bio Inc. (BXRX) and Viemed Healthcare Inc. (VMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BXRX and VMD operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- VMD is the larger of the two at $346.6M, about 23.6x BXRX ($14.7M).
- VMD has hit the wire 10 times in the past 4 weeks while BXRX has been quiet.
- VMD has more recent analyst coverage (2 ratings vs 0 for BXRX).
- Company
- Baudax Bio Inc.
- Viemed Healthcare Inc.
- Price
- -
- -
- Market cap
- $14.7M
- $346.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 10
- Recent ratings
- 0
- 2
Baudax Bio Inc.
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Viemed Healthcare Inc.
Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment and post-acute respiratory healthcare services to patients in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators; bi-level, continuous, and automatic continuous positive airway pressure (PAP) machines; and oxygen therapy, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services. It also provides in-home sleep apnea testing services to determine the existence of sleep apnea at home. In addition, the company leases non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units, and other respiratory equipment, as well as sells medical equipment and/or patient medical services. Further, it provides therapy and counseling to patients in their homes using its technology. The company was founded in 2006 and is headquartered in Lafayette, Louisiana.
Latest BXRX
- SEC Form 8-K filed by Baudax Bio Inc.
- SEC Form 25-NSE filed by Baudax Bio Inc.
- SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)
- SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)
- Baudax Bio Inc. filed SEC Form 8-K: Other Events
- CORRECTION: BioCryst Pharmaceuticals Ticker is "BCRX
- BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities
- SEC Form 424B3 filed by Baudax Bio Inc.
- SEC Form 10-Q filed by Baudax Bio Inc.
- SEC Form NT 10-Q filed by Baudax Bio Inc.
Latest VMD
- Barrington Research initiated coverage on Viemed Healthcare with a new price target
- Viemed Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Heltz Sabrina converted options into 18,786 shares and returned $33,588 worth of shares to the company (3,757 units at $8.94), increasing direct ownership by 22% to 82,520 units (SEC Form 4)
- Director Dobbs Randy E. converted options into 20,954 shares and returned $37,468 worth of shares to the company (4,191 units at $8.94), increasing direct ownership by 13% to 142,253 units (SEC Form 4)
- Director Kaushal Nitin converted options into 18,786 shares, increasing direct ownership by 13% to 161,361 units (SEC Form 4)
- Director Smokoff Timothy converted options into 18,786 shares and returned $33,588 worth of shares to the company (3,757 units at $8.94), increasing direct ownership by 20% to 90,547 units (SEC Form 4)
- SEC Form S-8 filed by Viemed Healthcare Inc.
- SEC Form 10-Q filed by Viemed Healthcare Inc.
- Viemed Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Viemed Healthcare Announces Second Quarter 2026 Financial Results